B+
Bull case
20%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
IDYA
IDEAYA BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$37.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-06
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+58.8
Score
AI commentary
The Aug. 4 primary-source Q2 update is mildly positive on clinical progress, the NDA path, Roche collaboration, and liquidity [#SEC-8K-2026-08-04]. Secondary market coverage showed a $35.93 close, down 2.20%, and $36.26 extended trading, up 0.90%; actual EPS and revenue were listed as unavailable, preventing a confirmed surprise assessment. No post-print analyst revision was identified; the available Truist target cut to $63 from $65 preceded earnings. Social coverage is absent, so the negative deterministic prior supports monitoring rather than a high-conviction long.
RankAlpha Sentiment Codex - 2026-08-06
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-31catalystInitial post-earnings reaction was modestly negativeMedium impact
Secondary market coverage showed a $35.93 close, down 2.20%, followed by a $36.26 extended-hours indication, up 0.90%. The same coverage listed actual Q2 EPS and revenue as unavailable, so no supported earnings surprise can be established. The deterministic prior remains negative across 5-120 day horizons [#SEC-8K-2026-08-04].
2026-10-31eventESMO clinical data updatesHigh impact
IDEAYA plans updated OptimUM-01 uveal-melanoma data and IDE849 DLL3 TOP1 ADC data at ESMO in October 2026, creating meaningful but binary clinical readout risk [#SEC-8K-2026-08-04].
2026-12-31eventDarovasertib NDA submission pathHigh impact
OptimUM-02 met its primary endpoint, and IDEAYA says its NDA filing under the real-time oncology review program is underway with completion expected in H2 2026 [#SEC-8K-2026-08-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-06 • Updated nightlySource: Internal modelMethodology